Bruce Trapnell is a Neonatal Respiratory Health Research physician affiliated with Cincinnati Children's Hospital Medical Center. OpenAlex indexes 317 publications with 21,075 citations (h-index 81); ClinicalTrials.gov lists 9 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Pulmonary Disease profiles in the findmyKOL directory.
Data verified 7 Sept 2026
Overview
Updated 15 Oct 2026
Bruce Trapnell, MD, is affiliated with Cincinnati Children's Hospital Medical Center. The public record shows 317 publications with 21,075 citations (h-index 81), centered on Neonatal Respiratory Health Research, Virus-based gene therapy research, Congenital Diaphragmatic Hernia Studies. It also documents an investigator role on 9 registered clinical trials, industry payments reported by 7 companies, 16 NIH-funded awards (1995–2026).
- Most recent indexed publication: 2026 · European respiratory review
- Top research focus: Neonatal Respiratory Health Research
- 9 registered trials on ClinicalTrials.gov
- Open Payments reporting from 7 companies
Generated from the cited public record · current as of 15 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 12 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 177.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 15 Oct 2026
Listed as an investigator on 9 registered studies on ClinicalTrials.gov. The most recent:
- The Longitudinal Evaluation of Autoimmune Pulmonary Alveolar Proteinosis
Sponsor: Children's Hospital Medical Center, Cincinnati
- Pioglitazone Therapy of Autoimmune Pulmonary Alveolar Proteinosis Autoimmune Pulmonary Alveolar Proteinosis
Sponsor: Children's Hospital Medical Center, Cincinnati
Industry payments
Updated 15 Oct 2026
7 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Kyowa Kirin Co., LtdProgram year20252 payments
- La Jolla Pharmaceutical CompanyProgram year20251 payment
- Partner Therapeutics, Inc.Program year20246 payments$15,261openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
30.4%Corticosteroid30.4%Prednisone100%Part D≥12 patientsBlood & clotting
26.7%Human alpha-1 Proteinase Inhibitor26.7%Prolastin C100%Part D<11 patientsRespiratory
24.4%beta2-Adrenergic Agonist16.3%Albuterol Sulfate Hfa100%Part D<11 patientsCorticosteroid8.1%Breo Ellipta100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 15 Oct 2026
16 NIH research awards on record, funded 1995–2026 per NIH RePORTER. The latest:
- Technology to understand genetic variant effects in context
University of Washington
FY2026$2,128,294RM1HG010461
Publications
Updated 15 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- The burden of autoimmune pulmonary alveolar proteinosis: a systematic review.
European respiratory review
Review2026 - Phase 3 Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis.
The New England journal of medicine
Clinical Trial2025 - Inhaled recombinant GM-CSF reduces the need for whole lung lavage and improves gas exchange in autoimmune pulmonary alveolar proteinosis patients.
The European respiratory journal
Clinical Trial2024 - Direct-to-Consumer Recruitment Methods via Traditional and Social Media to Aid in Research Accrual for Clinical Trials for Rare Diseases: Comparative Analysis Study.
Journal of medical Internet research
Article2023 - Identification of Distinct Inflammatory Programs and Biomarkers in Systemic Juvenile Idiopathic Arthritis and Related Lung Disease by Serum Proteome Analysis.
Arthritis & rheumatology (Hoboken, N.J.)
Article2022
Most-cited works
by citation count (OpenAlex)- 01Efficacy and Safety of Sirolimus in LymphangioleiomyomatosisArticle1,120 citations2011
- 02
- 03Pulmonary Alveolar ProteinosisArticle791 citations2003
- 04
- 05
Network
Updated 15 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Similar KOLs
Other experts from the same institution or the same specialty.
Andrea Beaton, MD
Cincinnati Children's Hospital Medical Center
Prasad Devarajan, MD
Cincinnati Children's Hospital Medical Center
Stuart Goldstein, MD
Cincinnati Children's Hospital Medical Center
Tracy Glauser, MD
Cincinnati Children's Hospital Medical Center
Fernando Martinez, MD
University of Massachusetts Chan Medical School
David Gozal, MD
Marshall University
Ronald Crystal, MD
Weill Cornell Medicine
Bartolome Celli, MD
Brigham and Women's Hospital